New hope for kids with rare muscle disease: drug trial launches
NCT ID NCT06987539
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 32 times
Summary
This study tests a drug called inebilizumab in 15 children aged 2 to 17 who have generalized myasthenia gravis, a disease that causes muscle weakness. The goal is to see how the drug moves through the body, how it affects immune cells, and whether it is safe. While the drug may help control symptoms, it is not a cure, and children may need ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Neuromuscular Center
RECRUITINGAustin, Texas, 78759, United States
Conditions
Explore the condition pages connected to this study.